



Distress Adherence and Quality of Life of Type 2 Diabetes mellitus patients in Indonesia

Dyah Aryani Perwitasari¹, Imaniar Noor Faridah¹, Woro Supadmi¹, Mentari Yulistika², Sitti Nurdjaja Soltief³, Elfride Irawati Sianturi⁴, Nurul Masyitoh⁵, Hafifah Jasman⁶, Ajeng Diantini⁷

¹Faculty of Pharmacy, University of Ahmad Dahlan, Kampus 3, Jl Prof Dr Soepomo, Janturan Yogyakarta, Indonesia.

¹Faculty of Pharmacy, University of Ahmad Dahlan, Kampus 3, Jl Prof Dr Soepomo, Janturan Yogyakarta, Indonesia.

¹Faculty of Pharmacy, University of Ahmad Dahlan, Kampus 3, Jl Prof Dr Soepomo, Janturan Yogyakarta, Indonesia.

²RSUD Panembahan Senopati Bantul, Jl Dr Wahidin Sudirohusodo, Bantul, Yogyakarta, Indonesia.

³RSUD DOK II Jayapura, Jl Kesehatan I No 01, Jayapura, Indonesia.

⁴Faculty of Pharmacy, University of Cendrawasih, Jl Camp Wolker, Jayapura, Indonesia.

⁵RSUD dr. Abdul Azis Singkawang, Jl Dr Soetomo no 28, Singkawang, Indonesia.

⁶RS Sansani, Jl Soekarno Hatta Atas, Pekanbaru, Indonesia.

⁷ Faculty of Pharmacy, University of Padjajaran, Jl Raya Bandung Sumedang, KM 21, Jatinangor, Bandung, Indonesia.

Corresponding Author: Dyah Aryani Perwitasari, Faculty of Pharmacy, University of Ahmad Dahlan, Kampus 3, Jl Prof Dr Soepomo, Janturan Yogyakarta, Indonesia.

Type of Publication: Original Research Paper

Conflicts of Interest: Nil

Abstract

Purpose: This study is aimed to determine the correlation among distress, adherence and quality of life of diabetic patients.

Methods: We used a cross-sectional design. Data were collected from diabetic patients at RSUD Abdul Azis Singkawang, West Kalimantan, Indonesia, RSUD Meranti and RSUD DOK II Jayapura during 2017 and 2018. Subjects were patients diagnosed with Type 2 Diabetes mellitus (T2DM), aged over 18, and under outpatient treatment at the hospitals in the aforementioned period. We used Diabetes-Distress Scale (DDS), Morisky Medication Adherence Scale-4 (MMAS-4) and EQ-5D to measure distress, adherence and quality of life, respectively. The Structural Equation Modelling (SEM)

was used to define the structure of distress, adherence and quality of life.

Results: We recruited 231 patients. The average of blood sugars were high (> 150 mg/dl). The four dimensions of DDS were moderate (< 3.0), most of the patients were in moderate risk of not adherence (55.76%), the index of EQ-5D was around 0.7 and the VAS was around 70%. The deterioration of quality of life is significantly influenced by moderate risk of non-adherence and moderated distress. The deterioration of quality of life is dominantly influenced by the moderate distress level. The moderate risk of non-adherence is correlated with moderate distress.

Conclusion: Patients' distress has significant correlation with adherence. Distress and adherence have significant correlation with quality of life. The moderate risk of non-

adherence of diabetic patients can cause the worse of clinical data, whereas can be the risk of diabetic complications. The psychological intervention can push the patients to cope with the disease and disease treatment.

Keywords: distress, adherence, QoL, diabetes, Indonesia.

1. Introduction

The prevalence of Type 2 Diabetes mellitus (T2DM) in the world has markedly increased. It is estimated that in 2030 the number of T2DM sufferers in Indonesia will reach 21.3 million¹. Basic Health Research reported that the highest T2DM prevalence occurred in the provinces of Riau (1.0 %), West Kalimantan (0.8 %) and Papua (0.8%)¹. Diabetes is a chronic disease which can affect patients' quality of life. Health-related quality of life is defines as the multidimensional perspective of patients toward the current condition. The dimensions measure in the perspective of health-related quality of life are physical, psychological, social, cognitive and spiritual². Health-related quality of life is one of the treatment's outcome which reflected the quality of health services. Quality of life is also associated with the quality of pharmaceutical care^{3,4}. Currently, the number of research about quality of life in chronic disease is getting increase. Most of the research also made association between predictors of other treatment outcome and quality of life⁵.

Some predictors of Health-related quality of life were age, duration of disease, number of drug prescribed, medication adherence and treatment satisfactory. Medication adherence is significantly associated with health-related quality of life. The increase of adherence can improve the quality of life. In T2DM patients, their quality of life significantly related to medication adherence³. The low adherence of T2DM patients was mainly due to the complexity of medicine regimens⁵. However, previous studies also mentioned that the adherence is not related to the health-related quality of life⁶. The contradictive reports could be due to the sample

size, population characteristics, the adherence method and the instruments that used in the study⁷.

The adherence T2DM patients in developed countries are low⁸⁻¹¹. Many factors can be contributed in this issue, such as; lower literacy, education and counselling session in the health care centers. Education level of the patients also became the barrier of communication between the patients and health care professionals⁵.

The T2DM patients also experienced emotional distress due to the limited physical activities, physician – relationship, interindividual-relationship and long term of treatment. Previous studies mentioned that 40% T2DM patients experienced depression and T2DM patients had 2-4 fold greater risk of depression compared to individual without T2DM¹²⁻¹⁴. Some patients' characteristics can predict the depression as the comorbidity such as; older patients, female sex, insulin treatment and the number of complication¹⁵.

According to the high prevalence of T2DM in Indonesia, the objectives of this study were to assess the distress scale, medication adherence and Health-related quality of life and to define the correlations among the scales. We plan to explore the distress, adherence and quality of life in T2DM patients using validated instruments in Bahasa Indonesian versions.

2. Methods

2.1. Participants

We used a cross-sectional design. Data were collected from diabetes patients at RSUD Abdul Azis Singkawang, West Kalimantan, Indonesia, RSUD Meranti and RSUD DOK II Jayapura during 2017 and 2018. The target population was diabetes patients receiving outpatient services at the hospitals. Subjects who met the inclusion criteria were patients diagnosed with T2DM, aged over 18, and under outpatient treatment at the hospitals in the aforementioned period, whereas the ones excluded were

patients who were unwilling to participate in this study and those who were illiterate.

Prior to gathering data from every subject, they were asked for their willingness to partake in this research and to provide informed consent. The blood sampling was done after filling the questionnaires. Data collection resumes only if the patient complies. To facilitate data collection through questionnaires, the researchers accompanied the patients in answering the questions. This study has received approval from the Ethics Committee of the Faculty of Pharmacy at Universitas Ahmad Dahlan Yogyakarta, Indonesia, Number 011701003.

2.2. Questionnaires

The questionnaires utilized in this inquiry was the Indonesian version of Diabetes-Distress Scale (DDS)¹⁶. Polonsky et al. introduced the DDS on patients with type 1 and T2D at various settings. Patients were asked to express their concern about for 1 month on a Likert scale from 1 (not a problem) to 6 (a very serious problem). This questionnaire has four domains, which are; emotional burden, physician-related distress, regimen-related distress and diabetes-related inter-individual distress¹⁷. The distress scales were categorized into moderate (>2) and high (>3)¹⁸. Adherence was measured by Morisky Medication Adherence Scale which contains of four scale¹⁹. The adherence scales were categorized into i) adherent, for subjects who answered 'no' to all questions, ii) moderate risk of adherence for subjects who answered 'yes' in questions number 1 or 2 or in questions number 3 or 4, and iii) high risk of adherence for subjects who answer 'yes' in all questions²⁰. The quality of life was measured by Indonesian version of EQ5D, which interpreted into index of quality of life and also additional measurement of Visual Analog Scale²¹. All the questionnaires are available in Bahasa Indonesia and fulfilled the reliability and validity criteria.

2.3. Statistical Analysis

We analyzed the data using SmartPLS v.3 software. The Structural Equation Modelling (SEM) was running by SmartPLS v.3. The inner model was defined to evaluate the endogenous factors. Some of tests such as: discriminant validity, convergent validity and reliability were evaluated as endogenous factors. The path coefficient was determined to evaluate the exogenous model as the structural relationship, which can be seen from the standardized coefficient and significance.

3. Results and Discussion

We recruited 231 patients with 59% among them were male. Table 1 shows the T2DM patients' characteristics. According to the education, occupation, salary, marriage status, family history, most of the patients are high educated, good salary, having family and without family history of diabetic. The patients can survive with monotherapy for less than 5 years of diabetes and the treatment. The average of blood sugars measurements were high (> 150 mg/dl). The four dimensions of Diabetes Distress Scale were moderate (< 3.0), most of the patients were in the moderate risk of non adherence (55.76%), the index of EQ-5D was around 0.7 and the VAS was around 70%. The quality of life was deteriorate because the value of Indonesian health population is 0.921²².

In general, the diabetic patients in this study mostly have high of blood glucose, which can be seen from the clinical data such as; random blood glucose, fasting blood glucose, 2 hours-post prandial blood glucose and HbA1C. The average of disease duration of the patients is less than 5 years, in fact most of them are treated by metformin. Combining with the distress, adherence and quality of life, we can see that the patients experienced moderate distress, moderate-risk of non-adherence and the deterioration of quality of life value. Similar results are found in some previous studies, the previous study conducted in US with 139 diabetic patients, also had similar results that patients with uncontrolled T2DM also had depressive symptoms

and moderate distress²³. Diabetic patients in Malaysia also experienced moderate distress and had negative correlation with quality of life. However, the religiosity had positive impact to the quality of life²⁴. Furthermore, in United States population, diabetic patients was related with serious psychological distress and could diminish the quality of life²⁵.

According to the value of clinical data, the health professionals should be focused on this situation, because the treatment outcome has not been reached yet and most of the patients experienced macrovascular complications. The treatment change or treatment modification should be considered to get the normal treatment outcome. The combination of metformin with linagliptine or sulfonylurea in uncontrolled diabetic patients can be used as the treatment choices^{26,27}.

Tabel 1. Patients' characteristics and description of DDS, Adherence and QoL (n=231)

Characteristics	N (%)	Mean ± SD	Fasting Blood Glucose (mg/dl)	Random Blood Glucose (mg/dl)	2 hours pp Blood Glucose (mg/dl)	HbA1C (%)
Age		57.14 ± 9.4	<200	117 (50.64%)	184.60 ± 80.43	
Sex			≥200	114 (49.36%)		
Female	95 (41.12)					
Male	136 (58.88)					
Education			<200	109 (47.19%)	219.64 ± 85.11	
Under Senior High School	87 (37.66)		≥200	122 (52.81%)		
Above Senior High School	13 (62.34)					
Occupation						
Jobless	97 (41.99)					
Work	134 (58.01)		<200	67 (29.00%)	271.23 ± 22.7	
Salary (IDR)			≥200	164 (70.99%)		
< 2.200.000	103 (44.59)					
≥ 2.200.000	128 (55.41)					
Marriage Status			4.4-6.4	37 (16.01%)	8.68 ± 2.58	
Married	213 (92.2%)		6.4-7.4	35 (15.15%)		
Single	18 (7.8%)		≥7.5	159 (68.84%)		

		DD2	0,678
DDS (moderate)		DD3	0,734
Emotional-related distress	2.31 ± 1.28	DD4	0,758
Physician-related distress	2.35 ± 1.27	E1	0,737
Management-related distress	2.55 ± 1.08	E2	0,547
Interindividual-related distress	2.07 ± 1.25	E3	0,743
Adherence		E4	0,728
Adherent	58 (26.73%)	E5	0,727
Moderate risk of non adherence	121 (55.76%)	p-1	0,676
High risk of non adherence	38 (17.51%)	p-2	0,806
VAS	71.45 ± 14.44	p-3	0,564
Index of EQ5D	0.78 ± 0.25	p-4	0,655

Patients had moderate distress in the scale of emotional, physician, management and inter-individual. These distresses should be treated by some psychological intervention then it could be increase the patient's adherence. Previous study mentioned that cognitive and/or behavioural intervention for 12 months showed more effective outcomes ²³. A systematic review with 30 randomized controlled trials and 9177 subjects concluded that some evidences showed the effective treatment outcome after psychological interventions ³¹. Still in Malaysian study, medication adherence positive correlation with quality of life, meaning that an intervention to adherence could improve quality of life ³². Continuously, the high adherence will increase the patients' quality of life, because the positive correlation between distress-adherence and adherence-quality of life. Table 2 shows the results of SEM about the convergent validity of all indicators. All indicators met the criteria of convergent validity with the p value > 0.5.

Table 2. Convergen validity (>0.5)

	Adherence	Distress	QoL
DD1		0,760	

According to the discriminant validity, it can be seen that all the indicators were highly correlated with their own latent variables (Table 3). Table 4 shows the results of reliability test based on Cronbach alpha, composite reliability and Average Variance Extracted (AVE). All the latent variables met the criteria for the three reliability parameters, except for the adherence which did not meet the AVE criteria (>0.5).

Table 3. Discriminant validity

	Adherence	Distress	Index	QoL	VAS
DD1	0,316	0,760	0,041	0,322	-0,055
DD2	0,297	0,678	0,213	0,067	0,163
DD3	0,317	0,734	0,021	0,196	0,051
DD4	0,275	0,758	0,106	0,277	-0,055
E1	0,104	0,205	-	0,737	-0,443
E2	-0,052	0,046	-	0,547	-0,312
E3	0,059	0,143	0,013	0,743	-0,399
E4	0,044	0,155	0,210	0,728	-0,355
E5	0,173	0,322	0,305	0,727	-0,189
IND	0,087	0,122	1,000	0,186	0,043
VAS	0,140	0,023	0,043	-	1,000

				0,441		
p-1	0,676	0,182	0,088	0,113	0,081	
p-2	0,806	0,328	0,101	0,213	0,152	
p-3	0,564	0,170	0,010	-	0,107	
				0,045		
p-4	0,655	0,227	0,074	-	0,161	
				0,021		

Bold number: meet the discriminant validity

Table 4 Reliability based on Cronbach alpha, Composite Reliability and Average Variance Extracted (AVE)

	Cronbach's Alpha	Composite Reliability	Average Variance Extracted (AVE)
Adherence	0,700	0,801	0,302
Distress	0,715	0,823	0,538
QoL	0,776	0,826	0,50

The inner model analysis resulted the R square as can be seen in Table 5. The R square value is the determinat of endogenous construct. The R square of this model is weak because the value is less than 0.19. Distress can explained the adherence as much as 11%. Index is inflenced by distress through adherence as much as 1.9% and index is directly influenced by distress as much as 11%. QoL is influenced by distress thourgh index as much as 9.6%. VAS is influenced by distress through adherence, index and QoL as much as 3.3%.

Table 5. R Square of endogenous construct

	R Square
adherence	0,110
index	0,019
qol	0,096
vas	0,033

This model is valid and reliable, because the results of outer model shows that the models meet the criteria for discriminant validity, convergent validity and the

reliability based on Cronbach alpha, composite reliability and AVE.


Table 6 shows the path coefficients of distress, adherence and QoL model. The significant correlation can be seen from the correlation between adherence and vas, distress and adherence, distress and QoL. The adherence had positive correlation with VAS ($\beta=0.19$; $p=0.011$). The distress also has positive correlation with adherence and QoL ($\beta=0.33$; $p=0.000$ and $\beta=0.30$; $p=0.000$, respectively). In general, the path coefficient shows that the higher adherence, the higher quality of life,; the higher distress, the higher adherence; and the higher distress, the higher quality of life.

According to the structured model in Fig 1, the deterioration of quality of life is significantly influenced by moderate-risk of non-adherence and moderated distress. Even though, the correlation value is weak because less than 10%. The deterioration of quality of life is dominantly influenced by the moderate distress level. The value of distress scale are in the category of moderate distress level, so that the value of quality of life is good (around 0.7).

Table 6. Path coefficient of distress, adherence and QoL model

	Original Sample	Mean	SD	T stat	P Values
adherence -> index	0,072	0,071	0,078	0,929	0,354
adherence -> qol	0,028	0,033	0,095	0,296	0,767
adherence -> vas	0,190	0,194	0,074	2,554	0,011*
distress -> adherence	0,332	0,339	0,048	6,847	0,000*
distress -> index	0,120	0,118	0,083	1,450	0,148
distress -> qol	0,308	0,334	0,071	4,321	0,000*
distress -> vas	0,021	0,013	0,106	0,197	0,844

Index= 0.072 adherence + 0.120 distress; QoL= 0.028 adherence + 0.308 distress; VAS= 0.190 adherence + 0.021 distress; Adherence= 0.332 distress



DD (1-4); indicators of distress; p (1-4): indicators of adherence; E (1-5): indicators of QoL; VAS: Visual Analog Scale; IND: Index of QoL

Fig 1. Structural Model

This present study shows the moderate risk of non-adherence which is correlated with moderate distress. The positive correlation between adherence and distress could be explained that the complexity of treatment, disease and lifestyle could cause the distress, but it can also increase the adherence. Some of the supporting factors like family support should be consider as the way to decrease the distress. The previous study in Malaysia about distress, adherence and quality of life depicted that patients with low level of distress had high adherence and quality of life. Thus, some intervention which can help the patients to cope with the disease and disease treatment may decrease the distress²⁸. The previous studies in Germany and Taiwan showed similar results with this present study due to the significant correlation between adherence and quality of life^{29,30}.

The SEM analysis can be used to understand the framework of QoL construct development. One of the treatment outcomes for the diabetic patients is to increase the patient's quality of life. Thus, factors that can predict the quality of life can be structured by SEM. This study

has limitation, we did not consider the variability of age, sex, treatment and other patients' characteristics in the structured analysis. Also we did not consider the differences of cultures in the three area over Indonesia. Every cultures has its own habit to overcome distress and to cope with the disease.

4. Conclusion

Patients' distress has significant correlation with adherence. Continuously, distress and adherence have significant correlation with quality of life. The moderate risk of non- adherence of diabetic patients can cause uncontrolled of clinical data, whereas can be the risk of diabetic complications. The psychological intervention can push the patients to cope with the disease and disease treatment. Furthermore, the distress level will decrease and can increase the adherence. Quality of life as one of the treatment outcomes can describe whether the treatment is effective or not.

5. Acknowledgments

The authors thank to Ministry of Research, Technology and Higher Education, Indonesia; staffs in DOK II Hospital, Jayapura, Abdul Azis Hospital ,Singkawang and Meranti Hospital for the support of permission and the application of the model structured.

8. References

1. Health M of. Basic Health Research. 2013. <http://labmandat.litbang.depkes.go.id/riset-badan-litbangkes/menu-risikesnas/menu-risikesdas/374-rkd-2013>. Published 2013. Accessed August 20, 2018.
2. El Achhab Y, Nejjari C, Chikri M, Lyoussi B. Disease-specific health-related quality of life instruments among adults diabetic: A systematic review. *Diabetes Res Clin Pract.* 2008;80(2):171-184. doi:10.1016/j.diabres.2007.12.020.
3. Iqbal Q, Ul Haq N, Bashir S, Bashaar M. Profile and predictors of health related quality of life among type II diabetes mellitus patients in Quetta city, Pakistan. *Health*

- Qual Life Outcomes.* 2017;15(1):142. doi:10.1186/s12955-017-0717-6.
4. Memel D. Chronic disease or physical disability? The role of the general practitioner. *Br J Gen Pract.* 1996;46(403):109-113.
5. Manan MM, Husin AR, Alkhoshaiban AS, Al-Worafi YMA, Ming LC. Interplay between Oral Hypoglycemic Medication Adherence and Quality of Life among Elderly Type 2 Diabetes Mellitus Patients. *J Clin Diagn Res.* 2014;8(12):JC05-9. doi:10.7860/JCDR/2014/10481.5309.
6. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. *Emerg Infect Dis.* 2010;16(10):1546-1553. doi:10.3201/eid1610.100374.
7. Martinez Y V, Prado-Aguilar CA, Rascon-Pacheco RA, Valdivia-Martinez JJ. Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross-sectional study. *BMC Health Serv Res.* 2008;8:164. doi:10.1186/1472-6963-8-164.
8. Letchuman GR, Wan Nazaimoon WM, Wan Mohamad WB, et al. Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006. *Med J Malaysia.* 2010;65(3):180-186.
9. Burkhart P V, Sabate E. Adherence to long-term therapies: evidence for action. *J Nurs Scholarsh an Off Publ Sigma Theta Tau Int Honor Soc Nurs.* 2003;35(3):207.
10. Rizkifani S, Perwitasari DA. Health-Related Quality of life of Diabetes Mellitus Patients in PKU Muhammadiyah Bantul Hospital. *Farmasisains.* 2014;2(3).
11. Perwitasari DA US. Treatment Adherence and Quality of Life in Diabetes Mellitus Patients in Indonesia. *Sage Open.* 2016;6(2):1-7.
12. Mushtaque A, Gulati R, Hossain MM, Azmi SA. Prevalence of depression in patients of type 2 diabetes mellitus: A cross sectional study in a tertiary care centre. *Diabetes Metab Syndr.* 2016;10(4):238-241. doi:10.1016/j.dsx.2016.06.016.
13. Golden SH, Shah N, Naqibuddin M, et al. The Prevalence and Specificity of Depression Diagnosis in a Clinic-Based Population of Adults With Type 2 Diabetes Mellitus. *Psychosomatics.* 2017;58(1):28-37. doi:10.1016/j.psych.2016.08.003.
14. Badescu S V, Tataru C, Kobylinska L, et al. The association between Diabetes mellitus and Depression. *J Med Life.* 2016;9(2):120-125.
15. Rajput R, Gehlawat P, Gehlan D, Gupta R, Rajput M. Prevalence and predictors of depression and anxiety in patients of diabetes mellitus in a tertiary care center. *Indian J Endocrinol Metab.* 2016;20(6):746-751. doi:10.4103/2230-8210.192924.
16. Polonsky, W.H., Fisher, L., Earles, J. E Al. Assessing Psychosocial Distress in Diabetes. *Diabetes Care.* 2005;28(3):626-631.
17. Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of Diabetes-Related Distress. *Diabetes Care.* 1995;18(6):754-760.
18. Aljuaid MO, Almutairi AM, Assiri MA, Almalki DM, Alswat K. Diabetes-Related Distress Assessment among Type 2 Diabetes Patients. *J Diabetes Res.* 2018;2018:7328128. doi:10.1155/2018/7328128.
19. Lam WY, Fresco P. Medication Adherence Measures: An Overview. *Biomed Res Int.* 2015;2015:217047. doi:10.1155/2015/217047.
20. Zweben A, Piepmeier ME, Fucito L, O'Malley SS. The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial. *J Subst Abuse Treat.* 2017;77:72-78. doi:10.1016/j.jsat.2017.04.001.
21. Purba FD, Hunfeld JAM, Fitriana TS, et al. Living in uncertainty due to floods and pollution: the health status and quality of life of people living on an unhealthy riverbank. *BMC Public Health.* 2018;18(1):782. doi:10.1186/s12889-018-5706-0.

- 22.Purba FD, Hunfeld JAM, Iskandarsyah A, et al. The Indonesian EQ-5D-5L Value Set. *Pharmacoeconomics*. 2017;35(11):1153-1165. doi:10.1007/s40273-017-0538-9.
- 23.Lutes LD, Cummings DM, Littlewood K, et al. COMRADE: A randomized trial of an individually tailored integrated care intervention for uncontrolled type 2 diabetes with depression and/or distress in the rural southeastern US. *Contemp Clin Trials*. 2018;70:8-14. doi:10.1016/j.cct.2018.04.007.
- 24.Chew B-H, Mohd-Sidik S, Shariff-Ghazali S. Negative effects of diabetes-related distress on health-related quality of life: an evaluation among the adult patients with type 2 diabetes mellitus in three primary healthcare clinics in Malaysia. *Health Qual Life Outcomes*. 2015;13:187. doi:10.1186/s12955-015-0384-4.
- 25.Dismuke CE, Hernandez-Tejada MA, Egede LE. Relationship of serious psychological distress to quality of life in adults with diabetes. *Int J Psychiatry Med*. 2014;48(2):135-146. doi:10.2190/PM.48.2.f.
- 26.Takahashi H, Nishimura R, Tsujino D, Utsunomiya K. Which is better, high-dose metformin monotherapy or low-dose metformin/ linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy: A randomized,. *J Diabetes Investig*. September 2018. doi:10.1111/jdi.12922.
- 27.Wang J-S, Lin S-D, Lee W-J, et al. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. *Clin Ther*. 2011;33(12):1932-1942. doi:10.1016/j.clinthera.2011.10.014.
- 28.Jannoo Z, Wah YB, Lazim AM, Hassali MA. Examining diabetes distress, medication adherence, diabetes self-care activities, diabetes-specific quality of life and health-related quality of life among type 2 diabetes mellitus patients. *J Clin Transl Endocrinol*. 2017;9:48-54. doi:10.1016/j.jcte.2017.07.003.
- 29.Wang R-H, Wu L-C, Hsu H-Y. A path model of health-related quality of life in type 2 diabetic patients: a cross-sectional study in Taiwan. *J Adv Nurs*. 2011;67(12):2658-2667. doi:10.1111/j.1365-2648.2011.05701.x.
- 30.Ose D, Miksch A, Urban E, et al. Health related quality of life and comorbidity. A descriptive analysis comparing EQ-5D dimensions of patients in the German disease management program for type 2 diabetes and patients in routine care. *BMC Health Serv Res*. 2011;11:179. doi:10.1186/1472-6963-11-179.
- 31.Chew BH, Vos RC, Metzendorf M-I, Scholten RJ, Rutten GE. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. *Cochrane database Syst Rev*. 2017;9:CD011469. doi:10.1002/14651858.CD011469.pub2.
- 32.Chew B-H. Medication adherence on quality of life among adults with type 2 diabetes mellitus: an exploratory analysis on the EDDMQoL study. *Qual Life Res*. 2015;24(11):2723-2731. doi:10.1007/s11136-015-1006-7.